The company will use the proceeds from the financing to support clinical trials for FX-909, a small molecule inhibitor targeting the peroxisome proliferator-activated receptor gamma (PPARG).
Additionally, the company will look to nominate at least one other development candidate from the company’s research pipeline in 2024, according to a March 22 Flare news release.
GordonMD Global Investments co-led the round with Pfizer.
“Transcription factors have long been viewed as prime therapeutic targets playing a key role in a broad range of diseases, particularly cancers, where they represent one-third of all oncogenes. While targeting transcription factors has the potential for incredible impact, their complex structure makes them notoriously difficult to drug, requiring a new approach and new thinking,” Flare Chief Scientific Officer and co-founder Rob Sims, PhD, said in the release.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.